Natixis Advisors LLC Buys 5,846 Shares of STERIS plc $STE

Key Points

• Natixis Advisors LLC raised its stake in STERIS by 4.0%, buying 5,846 shares to hold 151,822 shares worth about $37.57M, and institutional investors collectively own 94.69% of the company.
• Analysts give STERIS a consensus rating of "Moderate Buy" with an average price target of $275.20 (six Buys, two Holds), and Wall Street Zen recently upgraded the stock to "Strong-Buy."
• STERIS reported Q EPS of $2.53 (in line with estimates) with revenue up 9.2% y/y, set FY2026 guidance of $10.150–$10.300 EPS, and declared a $0.63 quarterly dividend (annualized $2.52, ~1.1% yield).

Natixis Advisors LLC increased its stake in shares of STERIS plc (NYSE:STE - Free Report) by 4.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,822 shares of the medical equipment provider's stock after buying an additional 5,846 shares during the quarter. Natixis Advisors LLC owned about 0.15% of STERIS worth $37,567,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Mediolanum International Funds Ltd increased its position in shares of STERIS by 9.0% in the second quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider's stock worth $14,883,000 after purchasing an additional 5,156 shares during the period. Entropy Technologies LP lifted its position in STERIS by 282.2% during the second quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider's stock worth $2,186,000 after purchasing an additional 6,718 shares during the period. Vanguard Group Inc. lifted its position in STERIS by 1.7% during the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider's stock worth $2,921,827,000 after purchasing an additional 205,276 shares during the period. Asset Management One Co. Ltd. grew its stake in STERIS by 5.4% during the third quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider's stock worth $24,366,000 after buying an additional 5,072 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in STERIS by 9.4% during the third quarter. Dimensional Fund Advisors LP now owns 1,039,351 shares of the medical equipment provider's stock worth $257,157,000 after buying an additional 89,250 shares in the last quarter. Institutional investors own 94.69% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wall Street Zen raised shares of STERIS from a "buy" rating to a "strong-buy" rating in a report on Saturday. Weiss Ratings reiterated a "buy (b)" rating on shares of STERIS in a research report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $275.20.

STERIS Price Performance

STERIS stock opened at $227.60 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. STERIS plc has a 52 week low of $204.90 and a 52 week high of $269.44. The stock has a market capitalization of $22.32 billion, a P/E ratio of 31.74 and a beta of 1.05. The stock has a fifty day moving average of $253.80 and a 200-day moving average of $251.42.

STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same period last year, the firm earned $2.32 EPS. The firm's revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, sell-side analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, February 17th. STERIS's dividend payout ratio (DPR) is presently 35.15%.

Insider Buying and Selling at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director directly owned 705 shares of the company's stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.07% of the company's stock.

STERIS Company Profile

STERIS Corporation NYSE: STE is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.